title: Antibacterial effect of plasma rich in growth factors (PRGF®-Endoret®) against Staphylococcus aureus and Staphylococcus epidermidis strains.
abstract: BACKGROUND
  Formulations containing plasma rich in growth factors (PRGF) are opening new avenues in the field of regenerative medicine.
  
  
  OBJECTIVE
  To evaluate the potential antimicrobial effects of a product (plasma rich in growth factors; PRGF(®)-Endoret(®)) against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. The potential effect of incorporating the patient's leucocytes into the PRGF formulation (F3+leu) was also studied.
  
  
  METHODS
  Blood samples were obtained from five healthy volunteers and used to prepare each type of PRGF (F1, F3 and F3+leu). Various biological assays were performed to compare the characteristics of the different formulations, including measurement of the concentration of platelets and leucocytes, and assays of coagulation. The microbiological activity of PRGF-Endoret against both staphylococcal strains was performed by counting the number of the surviving bacterial colonies after incubation at 0, 4 and 8 h with the different formulations.
  
  
  RESULTS
  The three PRGF-Endoret formulations evaluated were enriched in platelets by 1.10, 2.57 and 1.89 times, respectively, and the leucocyte concentration in the F3+leu sample was increased by 3.9 times. We found that all formulations had a strong bacteriostatic effect, especially in the first 4 h after application. All formulations had an antibacterial effect at 4 h for three of the four strains, with the exception of methicillin-sensitive S. epidermidis. No differences in the bacterial inhibitory effect were found between the formulations.
  
  
  CONCLUSIONS
  This is the first time different formulations of this product have been evaluated, and the results suggest that PRGF-Endoret could be used in the fight against postoperative and wound infections.
authors.affiliation: Biotechnology Institute (BTI ImasD), Vitoria, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Anitua
authors.forename: R
authors.initials: R
authors.lastname: Alonso
authors.forename: C
authors.initials: C
authors.lastname: Girbau
authors.forename: J J
authors.initials: JJ
authors.lastname: Aguirre
authors.forename: F
authors.initials: F
authors.lastname: Muruzabal
authors.forename: G
authors.initials: G
authors.lastname: Orive
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests; D010949:Plasma / Q000378:metabolism*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D036341:Intercellular Signaling Peptides and Proteins